Table 1. Clinicopathologic... | American Society of Hematology

Table 1.

Clinicopathologic characteristics of 23 patients with STAT3 SH2 domain variants

Age, y	Sex	NGS indication	Specimen	All somatic variants detected on NGS panel (VAF %)	T-cell clonality*	Splenomegaly	WBCs, ×10⁹/L	Neutrophil count, ×10⁹/L	Lymphocyte count, ×10⁹/L	Hgb, g/dL	Platelets, ×10⁹/L	Follow-up, mo†
45	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (13.8)	Yes	No	1.16	0.31	0.6	14.6	106	14.7
55	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (14.9)‡	Yes	No	3.27	0.97	1.81	14.0	212	4.2
51	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (19.4)	Yes	Yes	4.6	1.15	3.04	11.4	187	13.0
69	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (2.3)	Yes	No	3.23	1.36	1.54	9.5	51	24.5
				STAT3 c.1165T>C p.T389A (10.7)
29	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (25.2)	Yes	Yes	5.88	1.3	3.87	15.2	145	0
61	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (3.4)	Yes	Yes	0.9	0.24	0.5	11.4	95	0
71	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (32.7)	Yes	No	16.02	1.97	12.75	13.2	225	12.1
45	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (35.7)	Yes	No	10.78	1.29	7.76	12.8	255	13.1
				BRAF c.1781A>G p.D594G (4.7)
49	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (4.2)	Yes	No	2.04	0.33	1	13.8	225	20.1
36	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (5.2)	Yes	No	1.13	0.57	0.49	12.2	121	7.0
60	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (5.6)	Yes	No	4.44	2.26	1.63	14.3	156	0
51	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (5.7)	Yes	Yes	2.9	2.38	0.47	13.2	167	25.7
33	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (6.2)	Yes	No	3.97	2.03	1.54	15.9	154	6.1
74	F	LGL leukemia	PB	STAT3 c.1940A>T p.N647I (14.1)§	ND	No	8.11	3.91	3.37	8.9	472	0
				CXCR4 NM_003467 c.702G>T p.K234N (16.3)
70	M	LGL leukemia	PB	STAT3 c.1940A>T p.N647I (19.3)	I¶	Yes	9.52	2.19	6.56	11.7	160	0.7
91	F	LGL leukemia	PB	STAT3 c.1981G>T p.D661Y (18.3)	Yes	No	9.15	2.65	5.5	9.8	223	12.3
				SETD2 c.1366C>T p.R456* (12.0)
				TET2 c.1999_2000insTG p.H667fs* (15.7)
83	M	LGL leukemia	PB	STAT3 c.1981G>T p.D661Y (22.7)	Yes	No	2.8	0.45	1.79	12.1	145	13.4
				SMC3 NM_005445 c.763C>T p.Q255* (10.0)
34	F	LGL leukemia	PB	STAT3 c.1993T>A p.I665F (9.0)	Yes¶	No	3.09	1.19	1.68	12.8	158	13.2
29	M	LGL leukemia	PB	STAT3 c.1993T>A p.I665F (9.7)	Yes	No	4.23	1.27	2.42	14.5	153	18.5
69	M	Reported MDS	BM	STAT3 c.1971_1971insAAG p.657insS (22.7)	Yes¶	No	2.48	1.17	1.02	8.0	349	24.7
75	M	Reported MDS	PB	STAT3 c.1919A>T p.Y640F (18.9)	Yes	No	2.02	0.28	1.18	14.4	220	8.9
75	M	Reported MDS	PB	STAT3 c.1919A>T p.Y640F (6.9)	Yes¶	Yes	8.99	3.38	4.46	10.0	249	16.1
76	F	Reported MDS	BM	STAT3 c.1919A>T p.Y640F (12.9)	Yes	Yes	1.11	0.13	0.83	8.6	87	1.3

Age, y	Sex	NGS indication	Specimen	All somatic variants detected on NGS panel (VAF %)	T-cell clonality*	Splenomegaly	WBCs, ×10⁹/L	Neutrophil count, ×10⁹/L	Lymphocyte count, ×10⁹/L	Hgb, g/dL	Platelets, ×10⁹/L	Follow-up, mo†
45	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (13.8)	Yes	No	1.16	0.31	0.6	14.6	106	14.7
55	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (14.9)‡	Yes	No	3.27	0.97	1.81	14.0	212	4.2
51	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (19.4)	Yes	Yes	4.6	1.15	3.04	11.4	187	13.0
69	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (2.3)	Yes	No	3.23	1.36	1.54	9.5	51	24.5
				STAT3 c.1165T>C p.T389A (10.7)
29	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (25.2)	Yes	Yes	5.88	1.3	3.87	15.2	145	0
61	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (3.4)	Yes	Yes	0.9	0.24	0.5	11.4	95	0
71	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (32.7)	Yes	No	16.02	1.97	12.75	13.2	225	12.1
45	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (35.7)	Yes	No	10.78	1.29	7.76	12.8	255	13.1
				BRAF c.1781A>G p.D594G (4.7)
49	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (4.2)	Yes	No	2.04	0.33	1	13.8	225	20.1
36	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (5.2)	Yes	No	1.13	0.57	0.49	12.2	121	7.0
60	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (5.6)	Yes	No	4.44	2.26	1.63	14.3	156	0
51	F	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (5.7)	Yes	Yes	2.9	2.38	0.47	13.2	167	25.7
33	M	LGL leukemia	PB	STAT3 c.1919A>T p.Y640F (6.2)	Yes	No	3.97	2.03	1.54	15.9	154	6.1
74	F	LGL leukemia	PB	STAT3 c.1940A>T p.N647I (14.1)§	ND	No	8.11	3.91	3.37	8.9	472	0
				CXCR4 NM_003467 c.702G>T p.K234N (16.3)
70	M	LGL leukemia	PB	STAT3 c.1940A>T p.N647I (19.3)	I¶	Yes	9.52	2.19	6.56	11.7	160	0.7
91	F	LGL leukemia	PB	STAT3 c.1981G>T p.D661Y (18.3)	Yes	No	9.15	2.65	5.5	9.8	223	12.3
				SETD2 c.1366C>T p.R456* (12.0)
				TET2 c.1999_2000insTG p.H667fs* (15.7)
83	M	LGL leukemia	PB	STAT3 c.1981G>T p.D661Y (22.7)	Yes	No	2.8	0.45	1.79	12.1	145	13.4
				SMC3 NM_005445 c.763C>T p.Q255* (10.0)
34	F	LGL leukemia	PB	STAT3 c.1993T>A p.I665F (9.0)	Yes¶	No	3.09	1.19	1.68	12.8	158	13.2
29	M	LGL leukemia	PB	STAT3 c.1993T>A p.I665F (9.7)	Yes	No	4.23	1.27	2.42	14.5	153	18.5
69	M	Reported MDS	BM	STAT3 c.1971_1971insAAG p.657insS (22.7)	Yes¶	No	2.48	1.17	1.02	8.0	349	24.7
75	M	Reported MDS	PB	STAT3 c.1919A>T p.Y640F (18.9)	Yes	No	2.02	0.28	1.18	14.4	220	8.9
75	M	Reported MDS	PB	STAT3 c.1919A>T p.Y640F (6.9)	Yes¶	Yes	8.99	3.38	4.46	10.0	249	16.1
76	F	Reported MDS	BM	STAT3 c.1919A>T p.Y640F (12.9)	Yes	Yes	1.11	0.13	0.83	8.6	87	1.3

BM, bone marrow; F, female; Hgb, hemoglobin; M, male; ND, no data; I, indeterminate; NGS, next-generation sequencing; PB, peripheral blood; WBCs, white blood cells.

T-cell clonality determined by BIOMED-2 TCR-γ clonality assay.

†

All patients alive with disease at follow-up.

‡

Concomitant rheumatoid arthritis.

Also germ line STAT3 NM_139276 c.832C>T p.R278C (VAF 48.2%).

NK cell–like immunophenotyped (sCD3-CD16⁺).

View Large